Firms

Mammoth Scientific

Mammoth Scientific is a venture capital firm focused on health science and technology, including medical devices, biotechnology, healthcare software, financial technology and data-driven healthcare. Launched publicly in 2021, it combines physician entrepreneurs with investment, operating, legal and investor-relations specialists to support companies beyond seed stage through regulatory approval, reimbursement and commercialization. Published investments include MiRus medical devices and MRIguidance’s BoneMRI imaging technology. Mammoth Scientific, LLC is the private-fund adviser; Mammoth Investors, LLC is its parent management company, as disclosed in Vestia’s 2025 adviser brochure. Mammoth’s June 2024 legal disclosure describes an Indiana registration exemption. Its January 2024 SEC filing is an exempt-reporting-adviser final report, not evidence that the whole business closed. The website lists nine team members, with individual biographies sometimes providing more specific operating titles. The first health-and-technology fund advertises a $100 million target; this is not a verified final raise. Legal series are recorded separately where supported, with reported sold capital qualified to its filing date.

Founded: 2021
Type: Venture capital

Funds2

Mammoth Private Capital, LLC - Health & Tech Fund Series 1—$5M
Delaware legal fund series organized in 2021. May 26, 2023 Form D amendment reports $5,186,000 sold to 86 investors against a $40 million offering. This is subscribed capital as of the filing, not a verified final close; first sale May 6, 2021 is not used as a closing date. The broader public health-and-technology fund $100 million target is not allocated to this legal series.
Mammoth Private Capital, LLC - Health and Tech Fund Series 4——
Segregated Delaware special-purpose fund series designated in October 2021 and managed by Mammoth Scientific, LLC. The published Nsight offering targets a life-science company applying artificial intelligence and machine learning. The website says its investment period has closed, but actual subscribed capital and final closing date are not disclosed; the $1.5 million target is not recorded as raised cash.